(RTTNews) - Eton Pharmaceuticals Inc. (ETON) announced Tuesday that it has out-licensed commercial rights to Increlex in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. Esteve will ...

today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”). “Esteve shares Eton’s dedication to putt ...

(MENAFN- GlobeNewsWire - Nasdaq) Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ...

The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six ...

The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six ...

Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton” or the "Company”) (Nasdaq ...

Eton Pharmaceuticals (ETON) announced the out-licensing of commercial rights to Increlex in territories outside of the U.S. to Esteve Pharmaceuticals. “Esteve shares Eton’s dedication to putti ...